Genstar preempts Advarra process in ~$1.3 bln deal


healthcare, medical, private equity, pharma services, acquisition
sanjeri/E+/getty images
Preempting the highly anticipated sales process for PE-backed Advarra, Genstar Capital agreed to buy the provider of compliance-related services for clinical research, according to sources familiar with the matter. The pending acquisition values the Columbia, Maryland, company at about $1.3 billion ...

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.